IADR Abstract Archives

Age Comparisons in a RCT of Peri-implantitis Treatment With Minocycline-Microspheres

Objectives: The objective of the study is to evaluate the relation of age to the efficacy of Minocycline HCl 1mg Microspheres for the treatment of peri-implantitis used as an adjunct to mechanical debridement, when compared to debridement alone.
Methods: Two hundred eight (208) patients with implants diagnosed with peri-implantitis were enrolled in a multi-center trial and randomized to either mechanical debridement alone or mechanical debridement with the local administration of Minocycline HCl 1mg Microspheres. The primary outcome measure was probing depth reduction of qualifying implant sites at 6 months. Clinical assessments were performed at baseline, 3 and 6 months. Age subgroups (over fifty and below fifty) were analyzed for the primary outcome. Mixed model repeated measures was used to investigate the interaction of treatment by subgroup factor.
Results: In the total population, the subjects’ mean age was 61.4 years and 82.2% of the subjects were >50 years old. 50.5 % were male, 78.8% Caucasian, 16.8% Black, 2.9% Asian, 1% other, while 9.6% of subjects were smokers. The mean [SD] number of years since implant placement was 6.7 [4.05] years. Minocycline microspheres plus mechanical debridement provided more probing depth reduction than mechanical debridement alone in both subgroups (p=0.0244). Although Minocycline microspheres plus mechanical debridement provided more probing depth reduction than mechanical debridement alone in subjects ≤50 years than >50 years at 6 months, no evidence of interaction between the age subgroup and PD reduction was found (p=0.8711).
Conclusions: The adjunctive use of minocycline microspheres to the mechanical debridement of implants with peri-implantitis appears to provide an additional effect on the reduction of probing depths compared to mechanical debridement alone without any relation to the subjects’ age. Further studies including a bigger sample size of the young cohort are recommended.
Division: AADR/CADR Annual Meeting
Meeting: 2016 AADR/CADR Annual Meeting (Los Angeles, California)
Location: Los Angeles, California
Year: 2016
Final Presentation ID: 0888
Abstract Category|Abstract Category(s): Pharmacology/Therapeutics/Toxicology
Authors
  • Papathanasiou, Evangelos  ( Tufts University School of Dental Medicine , Boston , Massachusetts , United States )
  • Singh, Mabi  ( Tufts University , Boston , Massachusetts , United States )
  • Ramjit, Denise  ( Subsidiary of Valeant Pharmaceuticals International, Inc , Bridgewater , New Jersey , United States )
  • Cutler, Susan  ( Subsidiary of Valeant Pharmaceuticals International, Inc , Bridgewater , New Jersey , United States )
  • Papas, Athena  ( Tufts University , Boston , Massachusetts , United States )
  • Support Funding Agency/Grant Number: Supported by a Grant from Orapharma
    Financial Interest Disclosure: Susan Cutler: Director of Medical Affairs, OraPharma, Inc., Subsidiary of Valeant Pharmaceuticals International, Inc., 400 Somerset Corporate Boulevard, Bridgewater, NJ 08807 Denise Ramjit: Director, Clinical Operations, OraPharma, Inc., Subsidiary of Va
    SESSION INFORMATION
    Oral Session
    Novel Therapeutics for Familiar Ailments
    Friday, 03/18/2016 , 08:00AM - 09:30AM
    IMAGES